Does SECUKINUMAB Cause Focal segmental glomerulosclerosis? 5 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Focal segmental glomerulosclerosis have been filed in association with SECUKINUMAB (COSENTYX). This represents 0.0% of all adverse event reports for SECUKINUMAB.
5
Reports of Focal segmental glomerulosclerosis with SECUKINUMAB
0.0%
of all SECUKINUMAB reports
0
Deaths
0
Hospitalizations
How Dangerous Is Focal segmental glomerulosclerosis From SECUKINUMAB?
Of the 5 reports.
Is Focal segmental glomerulosclerosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SECUKINUMAB. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does SECUKINUMAB Cause?
Drug ineffective (27,434)
Psoriasis (21,976)
Pain (15,244)
Arthralgia (13,769)
Fatigue (9,406)
Psoriatic arthropathy (8,900)
Pruritus (8,755)
Malaise (8,570)
Rash (8,023)
Condition aggravated (7,536)
What Other Drugs Cause Focal segmental glomerulosclerosis?
TACROLIMUS (339)
MYCOPHENOLATE MOFETIL (181)
PREDNISONE (173)
CYCLOSPORINE (96)
METHYLPREDNISOLONE (81)
PREDNISOLONE (73)
RITUXIMAB (73)
BASILIXIMAB (67)
OMEPRAZOLE (60)
LANSOPRAZOLE (55)
Which SECUKINUMAB Alternatives Have Lower Focal segmental glomerulosclerosis Risk?
SECUKINUMAB vs SELADELPAR LYSINE
SECUKINUMAB vs SELEGILINE
SECUKINUMAB vs SELENIUM
SECUKINUMAB vs SELENIUM SULFIDE
SECUKINUMAB vs SELEXIPAG